ziltivekimab   Click here for help

GtoPdb Ligand ID: 11552

Synonyms: COR-001 | COR001 | MEDI-5117 | MEDI5117 | ZILTI
Compound class: Antibody
Comment: Ziltivekimab (MEDI5117) is a humanized monoclonal antibody directed against the IL-6 ligand. It was developed to inhibit pro-inflammatory IL-6 signalling in conditions that are associated with systemic inflammation, including atherosclerosis, chronic kidney disease, and rheumatoid arthritis [2], and it has also been explored for anti-tumour activity [4]. The Fc domain of ziltivekimab has been engineered to extend its half-life (by increasing affinity for FcRn), to support once-monthly administration [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Finch DK, Sleeman MA, Moisan J, Ferraro F, Botterell S, Campbell J, Cochrane D, Cruwys S, England E, Lane S et al.. (2011)
Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics.
J Mol Biol, 411 (4): 791-807. [PMID:21723291]
2. Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, Jeong HS, Chung SH. (2015)
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.
Arch Pharm Res, 38 (5): 575-84. [PMID:25648633]
3. Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS, Smith MT, Lo L, Herzog K, Kakkar R, Davidson MH. (2021)
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
J Am Soc Nephrol, 32 (1): 211-222. [PMID:33272965]
4. Zhong H, Davis A, Ouzounova M, Carrasco RA, Chen C, Breen S, Chang YS, Huang J, Liu Z, Yao Y et al.. (2016)
A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.
Cancer Res, 76 (2): 480-90. [PMID:26744529]